Kimia Akhavein, Caron A C Clark, Jennifer Mize Nelson, Kimberly Andrews Espy, Jenna E Finch
The Longitudinal Contributions of Preschool Executive Functions and Early Math Abilities to Arithmetic Skills in Elementary School
Cognitive development
norway comprehensive molecular tumour profiling implemented part public healthcare system substantial number tumours harbour potentially targetable molecular alterations therapy outcomes may improve targeted treatments matched actionable genomic alterations impressnorway trial nct04817956 patients treated drugs outside labelled indication based tumours molecular profile impressnorway national prospective nonrandomised precision cancer medicine trial offering treatment patients advancedstage disease progressing standard treatment comprehensive nextgeneration sequencing trusight oncology 500 used screening patients tumours harbouring molecular alterations matched targeted therapies available impressnorway offered treatment currently 24 drugs available study primary study endpoints percentage patients offered treatment trial disease control rate dcr defined complete partial response stable disease evaluable patients 16 weeks w16 treatment secondary endpoint presented dcr treated patients april 2021 october 2023 1167 patients screened actionable mutation matching drug identified 358 patients data cut 186 patients initiated treatment 170 minimum followup time 16 weeks 145 also evaluable disease patients evaluable disease dcr 40 58145 secondary endpoint analysis dcr treated patients showed dcr 34 58170 precision cancer medicine demonstrates encouraging clinical effect subset patients included impressnorway trial